Plicamycin
Cat. No.：YN250870
CAS No. ：18378-89-7
| 产品名称: | Plicamycin |
| CAS No.: | 18378-89-7 |
| Chemical Name: | (1S)-5-deoxy-1-C-[(2S,3S)-7-[[2,6-dideoxy-3-O-(2,6-dideoxy-β-D-arabino-hexopyranosyl)-β-D-arabino-hexopyranosyl]oxy]-3-[(O-2,6-dideoxy-3-C-methyl-β-D-ribo-hexopyranosyl-(1→3)-O-2,6-dideoxy-β-D-lyxo-hexopyranosyl-(1→3)-2,6-dideoxy-β-D-arabino-hexopyranosyl |
| Synonyms: | Mithramycin A |
| 分子量: | 1085.15 |
| 分子式: | C₅₂H₇₆O₂₄ |
| SMILES: | O=C([C@H]([C@@]([C@H](OC)C([C@@H](O)[C@H](O)C)=O)([H])C1)O[C@@](O[C@H](C)[C@H]2O)([H])C[C@H]2O[C@@](O[C@H](C)[C@@H]3O)([H])C[C@H]3O[C@@](O[C@H](C)[C@H]4O)([H])C[C@@]4(O)C)C(C1=CC5=CC(O[C@H](O[C@H](C)[C@H]6O)C[C@H]6O[C@@](O[C@H](C)[C@H]7O)([H])C[C@H]7O)=C( |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | Plicamycin 是一种选择性特Sp1转录因子抑制剂。Plicamycin 通过降低 Sp1 蛋白表达来抑制癌细胞生长。 |
| IC50和靶点: | |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Sleiman, S.F., Berlin, J., Basso, M., et al.Histone deacetylase inhibitors and mithramycin A impact a similar neuroprotective pathway at a crossroad between cancer and neurodegenerationPharmaceuticals4,1183-1195(2011)
Sleiman, S.F., Langley, B.C., Basso, M., et al.Mithramycin is a gene-selective Sp1 inhibitor that identifies a biological intersection between cancer and neurodegenerationJ. Neurosci.31(18),6858-6870(2011)
Lee, T.J., Jung, E.M., Lee, J.T., et al.Mithramycin A sensitizes cancer cells to TRAIL-mediated apoptosis by down-regulation of XIAP gene promoter through Sp1 sitesMol. Cancer Ther.5,2737-2746(2006)
Jia, Z., Gao, Y., Wang, L., et al.Combined treatment of pancreatic cancer with mithramycin A and tolfenamic acid promotes Sp1 degradation and synergistic antitumor activityCancer Res.70,1111-1119(2010)
Duverger, V., Murphy, A.M., Sheehan, D., et al.The anticancer drug mithramycin A sensitises tumour cells to apoptosis induced by tumour necrosis factor (TNF)Br. J. Cancer90,2025-2031(2004)
